Phase II Study of Sunitinib Malate in Refractory Germ Cell Tumors.
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 18 Dec 2014 Status changed from active, no longer recruiting to discontinued, as reported by M.D. Anderson Cancer Center record.
- 25 Apr 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 24 Apr 2012 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.